Compare FLXS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | GANX |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.8M | 159.2M |
| IPO Year | N/A | 2021 |
| Metric | FLXS | GANX |
|---|---|---|
| Price | $40.70 | $2.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 27.6K | ★ 2.2M |
| Earning Date | 02-02-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | ★ 64.53 | N/A |
| EPS | ★ 4.11 | N/A |
| Revenue | ★ $447,505,000.00 | N/A |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $3.04 | N/A |
| P/E Ratio | $9.47 | ★ N/A |
| Revenue Growth | ★ 6.00 | N/A |
| 52 Week Low | $29.38 | $1.41 |
| 52 Week High | $64.14 | $4.34 |
| Indicator | FLXS | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 38.50 |
| Support Level | $38.57 | $2.30 |
| Resistance Level | $41.43 | $3.29 |
| Average True Range (ATR) | 1.43 | 0.48 |
| MACD | -0.22 | -0.13 |
| Stochastic Oscillator | 43.65 | 19.33 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.